Seems to me that GNBT just shouldn't issue the dividend

New Post Public Reply Private Reply Replies (1) Message Board
homerbedloe
353
Seems to me that GNBT just shouldn't issue the dividend right now. The due bills remain with the shares being traded; I don’t think there is an expiration date associated with them. Once NGIO is spun off, and maybe a couple of other good news stories are released, hopefully we get a market cap in the couple of hundred million range. With only 43 million shares outstanding, that is still close to $5 per share which more than qualifies us for uplisting. Once that is accomplished, issue the dividend to those that have the due bills.

I tend to agree that CMF’s bad behavior doesn’t necessarily entitle others who signed the waiver to the dividend, but the attorneys will have to decide. I don’t think the other folks will sell their shares at $.80 - many of those shares came from deals where they were applied as currency at $2.50 a share. Why would the holders suddenly decided to take $.80/share for the controlling interest in their former stand alone companies, particularly with the potential pps gains if GNBT executes its plan?

I think Joe has some leverage with CMF at this point. He can obviously threaten a very public lawsuit that makes it very clear that CMF went back on their agreement, destroying their future credibility. He can also publicly leverage a SEC investigation into the improper filing of documents, as well as the breach of the agreement. Both of those actions will take time, but the PUBLIC release of the lawsuit and SEC investigation will be immediate, and should have a chilling effect on future CMF clients. And remember, the truth is an absolute defense against slander or libel, so if Joe is sure they broke the agreement, there is no counter-suit that has merit.

I suggest using that leverage with CMF as a counter to this deal:

1. They will buy back 2 million shares on the open market, starting on a specific date and finishing the purchase no more than 10 business days beyond the starting date. They can use any strategy to purchase the shares (evenly over the 10 days, wait and purchase all 2 million the last day, whatever), but at no time from now until when the purchase is completed are they allowed to sell or short any shares of GNBT, so the price of the shares cannot be manipulated by them. Keep the agreement and dates private between CMF and GNBT so nobody else can manipulate the purchases or the price of the shares.

2. All of the 2 million shares purchased and all other shares held by CFM will be restricted from sale for 3 years. Interestingly, if all goes as planned for GNBT, those shares will be worth much more than what they bought them at. The 2 million shares purchased will not be eligible for the dividend, whenever it is issued even if due bills are attached. Any dividend shares will either go back to GNBT or will have some other disposition that does not benefit CMF beyond owning the 2 million shares.

3. CFM must make a public statement that they breached the agreement with GNBT, and that they are making it right for GNBT and shareholders through a private agreement that will be fulfilled by a date certain. Details can and will be released once the agreement has been fulfilled. They can spin this anyway they want (rogue trader, oversight failure, whatever), but it should be made clear that it was CMF that screwed up, not GNBT. GNBT will make a statement that a private agreement has been reached that allows CMF to resolve an error, and again, details will be released after it has been fulfilled. The purchase of the 2 million shares will have to be filed with the SEC after they have been completed anyway.

4. Any dividend shares that they owe to purchasers of the original CFM shares will be paid out of the 2 million shares they currently hold. GNBT will be solely responsible for establishing when that dividend is paid.

The one wild card is whether the other restricted holders will toe the line or whether they will demand the divi shares. Again, I’m not so worried about them selling into the market, because that doesn’t benefit them regarding the sales prices for their companies. But as Joe has said, adding an additional 20 to 25 million shares to the outstanding count because of one bad apple hurts GNBT and its shareholders. I just hope the restricted holders understand this, and since they too are shareholders, will not demand the ability to receive the divi.

Probably there are three or four main issues here that might or might not meet regulatory oversight. That is what attorneys are for - work out the details where CMF can save themselves a lawsuit and save some face, while GNBT and shareholders receive a quick restitution for an illegal act. If that deal can be done quickly (say first quarter, 2020), and the other positives happen, CMF can make some money, GNBT can be made whole and shareholders will see an increasing pps.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Shift: From Tech Marvels to Practical Uses

Updated Category News Views 63

A New Chapter in the AI Narrative Take a seat, folks, because we're watching AI swing from showy tech to something as plain as plumbing infrastructure. Imagine models that once cost bundles per token now going for peanuts. We're talking a nosedive from $37.50 to a mere 18 cents. It’s a seismic shift, steering the conversation from 'Are they the best models?' to 'How...

Continue Reading
Terakeet's Game-Changer Moves: Mac Cummings' Vision

Updated Category News Views 74

Mac Cummings: A Maverick at Terakeet's Helm So, here’s the deal—we’ve got Mac Cummings, a guy who's shaking up the marketing world just when we thought we had it all figured out. When you get a nod from ADWEEK's Innovator 50, it isn't because you played it safe. It's because you believed in disrupting the status quo. Cummings has taken Terakeet from a humble start...

Continue Reading
Tea Extract Market Expansion: $4.7B by 2031 Forecast

Updated Category News Views 44

The Surging Demand for Tea Extracts The tea extract market's carving out quite a niche for itself. From $3.22 billion in 2026, it's primed to scale up to a cool $4.70 billion by 2031. That's a steady 7.9% growth rate, and it's just fueled by the booming demand for all things natural and health-oriented. Natural and Functional: Key Industry Drivers Consumers these days...

Continue Reading
China's Health-Driven Poverty Approach Offers Global Lessons

Updated Category News Views 28

China's Health Strategy in Poverty Reduction Here's a story that's got global implications tucked into its every corner: China, a country that's been trying to mesh healthcare with poverty reduction, has caught the eye of international observers. This insight was splashed across the latest Lancet Commission report, showcased at Tsinghua University on October 29. It seems...

Continue Reading
Tom Doyle Takes Helm at Gallagher's HR Consulting

Updated Category News Views 200

Leadership Shifts in Gallagher's Upper Echelons What a shake-up at Arthur J. Gallagher & Co.! The power torch is officially passing over in its Benefits & HR Consulting Division. Come January 1, 2027, Tom Doyle is strapping in as the new CEO, taking over from William F. "Bill" Ziebell. Now, don't get too teary-eyed—Ziebell's not vanishing into thin air. Instead, he's...

Continue Reading
Omnissa Expands AI Sovereignty: New Markets, New Control

Updated Category News Views 41

Omnissa Rolls Out AI Sovereignty Across New Markets In the world of AI, where data is king and control is the crown, Omnissa is making bold moves with its latest expansion announcement. The company's Sovereign Solution (OSS) is now reaching into six fresh markets across Europe and Asia, offering organizations a vital grip on their digital domains like never before. Talk...

Continue Reading
Q32 Bio Eyes New Horizons with Bempikibart's Potentials

Updated Category News Views 32

Q32 Bio Steers Forward: New Insights from Chief Results Today's update isn't just another quarterly snooze-fest—it’s a nudge in a crucial direction for Q32 Bio (NASDAQ:QTTB). After a bold brush with the European Academy of Dermatology and Venereology (EADV) Congress 2026, the company laid out a plan and a half, showing its hand with bempikibart for alopecia areata...

Continue Reading
Memoir 'Pinball' Explores Life's Unpredictable Momentum

Updated Category News Views 116

Funny how some folks think life has a road map. Let me tell you, it's more like a pinball machine, barely controllable and ready to surprise you with a tilt at any moment. And that's the essence of Marshall Barber's new memoir, 'PINBALL: Remembrances of a Flaneur.' Life's Roulette: Choices and Chance Barber takes readers on a raw ride through the byways of a life...

Continue Reading
Zayne Burgess Accelerates Towards Formula 1 with K1 Speed

Updated Category News Views 78

A Young Racer's Roaring Start Every once in a while, a kid shows up on the scene who just makes you sit up and pay attention. Enter Zayne Burgess, a mere 10-year-old with the skill set of a seasoned pro. If you care about the future of racing, you better start watching this young'un, because he's chasing a Formula 1 dream and has K1 Speed putting their chips on him....

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading

Top 5 Most Recently Viewed Articles

Insider Transactions and Financial Insights for Tanger Inc.

Updated Category News Views 120

Understanding Recent Insider Transactions at Tanger Inc. A noteworthy insider sell has surfaced recently, involving Joseph Thomas Guerrieri JR, who serves as Senior Vice President at Tanger (NYSE: SKT). The details of this transaction arose from a recent filing with the SEC, highlighting a substantial move by an insider. Transaction Overview: JR opted to divest 3,000...

Continue Reading
Transforming $100 Into Wealth With Charles Schwab Investments

Updated Category News Views 390

The Remarkable Growth of Charles Schwab Stock Over the past 20 years, Charles Schwab has consistently outperformed the overall market, showcasing a remarkable annualized return of 10.34%. This impressive performance has led to a market capitalization of approximately $141.73 billion. Understanding how this growth can translate for individual investors can provide valuable...

Continue Reading
Explore the New Seasons at Vista Del Sur Community Opening

Updated Category News Views 119

Exciting New Community Opening in Tolleson Richmond American Homes is thrilled to announce the grand opening of the Seasons at Vista Del Sur community. This new development promises to be a welcoming place for families and individuals looking to settle in a vibrant environment. With an impressive range of single- and two-story homes, Richmond American is committed to...

Continue Reading
Rocket Lab Selected by NASA for Innovative Mars Mission Study

Updated Category News Views 144

Rocket Lab Chosen for Groundbreaking NASA Mars Study Rocket Lab USA, Inc. (NASDAQ: RKLB) has an exciting opportunity in store as it embarks on a study for NASA's Mars Sample Return Program. This initiative is poised to be a historic endeavor, aiming to retrieve Martian rock samples and analyze them on Earth—offering unprecedented insights into Mars and the potential for...

Continue Reading
ASE Technology's Q2 Surge: Record Profits and Growth

Updated Category News Views 36

A Robust Quarter for ASE Technology Alright, sit down and buckle up because ASE Technology (NYSE: ASX) just dropped some eye-popping numbers for Q2 2026. This isn't some mild market fluctuation—this is what you call a serious win in the semiconductor game. With net revenues soaring to NT$191,064 million, it’s about 26.7% up from the same quarter last year. Now, that's...

Continue Reading